Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ClearPoint Neuro Inc (CLPT) vs Ralph Lauren Corp (RL) Price & Performance

ClearPoint Neuro IncTrade
Ralph Lauren CorpTrade

Price performance (Past 24H)

Key statistics

ClearPoint Neuro Inc vs Ralph Lauren Corp — how do they compare? ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M), while Ralph Lauren Corp trades at $397.75 (market cap $24.24B). The key difference: Ralph Lauren Corp is far larger — about 54.6× ClearPoint Neuro Inc's market cap, and Ralph Lauren Corp pays a 0.92% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.

CLPTRL
Market Cap
$444.14M$24.24B
Sector
HealthConsumer Cyclical
52-Week High
$29.60$414.25
52-Week Low
$8.66$285.35
Enterprise Value
$478.72M$25.31B
Dividend Yield
0.92%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.

The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.

Ralph Lauren Corp

Ralph Lauren (RL) trades at $395.53, down 0.08% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q1 2027 EPS of $4.59 exceeding expectations of $4.32, driven by robust demand and margin expansion. Revenue growth accelerated to 13% in constant currency, and the company updated its fiscal 2027 outlook upward. Key support lies at $388, with resistance at $402.

The investment outlook is positive, supported by earnings momentum, brand strength, and a 66% analyst buy rating. Risks include high valuation multiples, such as a P/E of 24.92, and sensitivity to consumer spending trends. The consensus price target of $456.50 implies 15% upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT

About Ralph Lauren Corp

Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.

Read more on RL